Holen Sie sich die Stockscreener-App
0.31
8.96%
-0.0305
Schlusskurs vom Vortag:
$0.3405
Offen:
$0.32
24-Stunden-Volumen:
232.12K
Relative Volume:
0.43
Marktkapitalisierung:
$12.52M
Einnahmen:
$45.91M
Nettoeinkommen (Verlust:
$-4.62M
KGV:
-2.2111
EPS:
-0.1402
Netto-Cashflow:
$-21.51M
1W Leistung:
-5.17%
1M Leistung:
-22.50%
6M Leistung:
-55.33%
1J Leistung:
-53.59%
1-Tages-Spanne:
$0.31
$0.348
1-Wochen-Bereich:
$0.27
$0.3618
52-Wochen-Spanne:
$0.27
$1.50
Equillium Inc Stock (EQ) Company Profile
Firmenname
Equillium Inc
Sektor
Branche
Telefon
(858) 412-5302
Adresse
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Vergleichen Sie EQ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.31 | 12.52M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2021-10-29 | Fortgesetzt | Stifel | Buy |
| 2021-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Equillium Inc Aktie (EQ) Neueste Nachrichten
Equillium Granted Extension for Nasdaq Compliance - TipRanks
Equillium (NASDAQ:EQ) Trading Down 6.1% – Time to Sell? - Defense World
Equillium expands equity incentive plan by 1.78 million shares - Investing.com Canada
Equillium Holds Annual Stockholders Meeting on Key Proposals - TipRanks
Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - BioSpace
Renaissance Technologies LLC Sells 59,773 Shares of Equillium, Inc. (NASDAQ:EQ) - Defense World
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Head-To-Head Survey: Equillium (NASDAQ:EQ) and KALA BIO (NASDAQ:KALA) - Defense World
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - BioSpace
FDA declines itolizumab accelerated approval, says Equillium - The Pharma Letter
Equillium shares fall following FDA feedback By Investing.com - Investing.com India
Equillium shares fall following FDA feedback - Investing.com Australia
Equillium Announces Feedback from the U.S. Food and Drug Adminis - GuruFocus
Equillium (EQ) Faces Setback as FDA Declines Accelerated Approva - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval By Investing.com - Investing.com Canada
Equillium (EQ) Faces FDA Setback for Itolizumab in Graft-versus-Host Disease Treatment | EQ Stock News - GuruFocus
FDA declines Equillium’s itolizumab accelerated approval - Investing.com
Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire
Equillium (NASDAQ:EQ) Shares Down 3.7% – Here’s Why - Defense World
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive - simplywall.st
Leerink Partnrs Forecasts Equillium FY2029 Earnings - Defense World
Leerink Partners Reaffirms “Market Perform” Rating for Equillium (NASDAQ:EQ) - Defense World
The week in pharma: action, reaction and insight – week to March 28 - The Pharma Letter
Leerink Partnrs Downgrades Equillium (NASDAQ:EQ) to Hold - Defense World
Leerink Partners Downgrades Equillium (LSE:0A4D) - Nasdaq
Equillium stock tumbles on Phase 3 study results By Investing.com - Investing.com India
Equillium stock tumbles on Phase 3 study results - Investing.com
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3 - MarketScreener
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - BioSpace
Equillium Reports 2024 Financials and Clinical Milestones - TipRanks
Equillium (EQ) Surprises with Smaller Q4 Loss Amid Revenue Dip - GuruFocus
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss - insights.citeline.com
Equillium reports mixed results in aGVHD study, seeks FDA fast track By Investing.com - Investing.com South Africa
Equillium pushes for breakthrough status despite missing primary endpoint - Yahoo Finance
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Benzinga
Equillium stock hits 52-week low at $0.49 amid market challenges - Investing.com Australia
Equillium fails to improve complete response in GVHD treatment study - Seeking Alpha
Nasdaq Down Over 100 Points; US Initial Jobless Claims Fall - Benzinga
Equillium drug fails main trial goal but shows longer-term promise - The Pharma Letter
Equillium, Inc. Announces Results of the Phase 3 Equator Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease - MarketScreener
Equillium reports mixed results in aGVHD study, seeks FDA fast track - Investing.com
Equillium Reports Phase 3 Results Of Itolizumab For Acute Graft-Versus-Host Disease - MarketScreener
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights - Joplin Globe
Finanzdaten der Equillium Inc-Aktie (EQ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Equillium Inc-Aktie (EQ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keyes Jason A | Chief Financial Officer |
Jan 23 '25 |
Sale |
0.65 |
10,000 |
6,500 |
37,720 |
| Keyes Jason A | Chief Financial Officer |
Nov 14 '24 |
Sale |
0.70 |
10,000 |
7,000 |
47,720 |
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):